Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from KYORIN Pharmaceutical Co.,Ltd. ( (JP:4569) ).
KYORIN Pharmaceutical Co., Ltd. released supplementary information on its consolidated financial results for the nine months ended December 31, 2025, covering business performance highlights, detailed financial outcomes, forecasts, main product sales trends, and the status of its development pipeline. The material is framed as investor-focused disclosure and emphasizes that its performance forecasts, goals, and development outlooks are subject to risks and uncertainties, underscoring that actual results and development progress may differ significantly, which is important for stakeholders evaluating the company’s prospects and risk profile.
The most recent analyst rating on (JP:4569) stock is a Hold with a Yen1725.00 price target. To see the full list of analyst forecasts on KYORIN Pharmaceutical Co.,Ltd. stock, see the JP:4569 Stock Forecast page.
More about KYORIN Pharmaceutical Co.,Ltd.
KYORIN Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing, and sale of prescription drugs and related healthcare products. The group focuses on developing medicines, including products under development, and provides consolidated financial reporting and forecasts covering its core pharmaceutical operations.
Average Trading Volume: 134,036
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen85.28B
For detailed information about 4569 stock, go to TipRanks’ Stock Analysis page.